Analyst Research Report Snapshot

Title:

Dendreon Corporation

Price:

$50.00

Provider:

MarketLine (a Datamonitor Company)

Date:

23 Jan 2013

Pages:

38

Type:

AcrobatPDF

Companies referenced:

DNDN.OQ

Available for Immediate Download
Summary:

Dendreon Corporation - Company Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, product and service offerings, and corporate actions, providing a 360° view of the company. Features: - Detailed information on Dendreon Corporation required for business and competitor intelligence needs - Intelligence on Dendreon Corporation’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Dendreon Corporation, such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Dendreon Corporation Company Profile is the essential source for top-level company data and information. Dendreon Corporation Company Profile examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy. Dendreon Corporation (Dendreon) is engaged in discovering, developing and commercializing therapeutics to improve cancer treatment options for patients. The company's product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. Dendreon's product candidate, PROVENGE (sipuleucel-T), an active cellular immunotherapy, is used for the treatment of metastatic and castrate-resistant prostate cancer. The company primarily operates in the US, where it is headquartered in Seattle, Washington and employs around 1,475 people. The company recorded revenues of $341.6 million in the fiscal year ended December 2011, as compared to the revenues of $48.1 million in 2010. The company's operating loss was $291.7 million in fiscal 2011, as compared to an operating loss of $292.2 million in 2010. Its net loss was $337.8 million in fiscal 2011, as compared to the net loss of $439.5 million in 2010. Scope of the Report - Provides all the crucial information on Dendreon Corporation required for business and competitor intelligence needs -Data is supplemented with details on Dendreon Corporation history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available statement from Dendreon Corporation Reasons to Purchase - Support sales activities by understanding your customers’ businesses better - Understand prospective partners and suppliers - Keep fully up to date on your competitors’ business structure, strategy and prospects - Obtain the most up to date company information available Reasons to Purchase: - Gain understanding of Dendreon Corporation the company and its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Dendreon Corporation as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Dendreon Corporation your competitors' business structure, strategy and prospects

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.